The legal cannabis industry is expanding rapidly worldwide. In North America alone, the industry is expected to grow from $9.2 billion in sales in 2017 to over $47 billion within ten years.
In the United States, cannabis is legal under state law for medical use in 30 states plus the District of Columbia, and for general adult recreational use in 9 states and the District of Columbia. But, at present, cannabis remains illegal under federal law. The tension, indeed the outright conflict, between state and federal law regarding marijuana creates both opportunities and risks for current and prospective operators and investors in the cannabis industry.
The Goodwin team has deep knowledge of the cannabis industry and understands the business and legal nuances that make it unique. Comprised of a cross-disciplinary group of lawyers, Goodwin’s Cannabis team covers the full spectrum of legal services needed by participants in the industry, including finding and developing investment opportunities, obtaining funding, structuring of transactions, M&A, protection of intellectual property, handling of government and regulatory investigations, advising clients regarding risks arising under federal law, and vigorous representation in all forms of litigation, all services subject to the firm’s obligations under federal law. As trusted advisors to our clients, we understand that as the legal environment evolves and the cannabis industry grows, the industry’s business needs will change. It is our priority to understand our clients’ business goals and to provide them with best-in-class service as this industry continues to grow and evolve.
Companies regulated by the Food and Drug Administration (FDA) know that expertise and practical advice are critical to the bottom line. Goodwin’s experienced FDA practice, a key component of the firm’s Technology & Life Sciences team, provides strategic counseling and skillful advocacy to companies subject to the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related federal and state laws.
Pharmaceutical companies need experienced counsel to protect their regulatory interests. Goodwin’s FDA Litigation practice provides counsel, representation and strategic advice that covers all aspects of our clients’ interactions with the Food and Drug Administration. Our lawyers regularly advise clients on regulatory issues, engage with the FDA and other federal and state agencies through Citizen Petitions, comments, meetings and other petitioning, and represent drug manufacturers in Administrative Procedure Act challenges.
Hedge fund markets are facing extraordinary challenges, including increased competition and a changing global regulatory environment. With extensive experience and resources in this industry, we help our hedge fund clients find opportunities, capitalize on them and provide better service to their investors.
We offer interdisciplinary expertise and an understanding of the “big picture” – which is critical for clients who offer their investors a wide ra
Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries around the world, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Lawyers in our life sciences practice are deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. We understand the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing product lines. As part of our interdisciplinary approach, we collaborate with attorneys in our patent litigation, products litigation, employment and tax practices to protect client interests and to advocate on their behalf.
With a full service team of highly experienced lawyers resident in key life sciences hubs, our team helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle. Motivated by the knowledge that the work that we do with you is improving people’s lives, we serve as an extension of your team so you can focus on your core business.
In the face of a competitive marketplace, elite private equity firms expect counsel with extensive experience and a stable of blue chip relationships. That’s why private equity firms have been entrusting their deals to Goodwin for decades. We believe our position to be unique within BigLaw given the collaboration of our private equity team with our robust life sciences, technology and healthcare practices. With our largest and strongest practices working together, Goodwin is exceptionally suited to address whatever the future brings.
Our Private Equity team ranks as one of the top in the United States, and we are on a trajectory of rapid ascent, both in the U.S. and abroad. The group is a market leader in the expansive middle market sector, having earned a reputation for notable buyouts, growth equity deals and growth company representations in key sectors such as technology, healthcare, financial and business services, consumer and manufacturing. And with the breakneck pace of technology disrupting industries around the world, we are uniquely positioned to partner with our clients and embrace the promise and potential of innovation.
Companies regulated by the Food and Drug Administration (FDA) know that expertise and practical advice are critical to the bottom line. Goodwin’s experienced FDA practice, a key component of the firm’s Technology & Life Sciences team, provides strategic counseling and skillful advocacy to companies subject to the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related federal and state laws.
Pharmaceutical companies need experienced counsel to protect their regulatory interests. Goodwin’s FDA Litigation practice provides counsel, representation and strategic advice that covers all aspects of our clients’ interactions with the Food and Drug Administration. Our lawyers regularly advise clients on regulatory issues, engage with the FDA and other federal and state agencies through Citizen Petitions, comments, meetings and other petitioning, and represent drug manufacturers in Administrative Procedure Act challenges.
Hedge fund markets are facing extraordinary challenges, including increased competition and a changing global regulatory environment. With extensive experience and resources in this industry, we help our hedge fund clients find opportunities, capitalize on them and provide better service to their investors.
We offer interdisciplinary expertise and an understanding of the “big picture” – which is critical for clients who offer their investors a wide ra
Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries around the world, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Lawyers in our life sciences practice are deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. We understand the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing product lines. As part of our interdisciplinary approach, we collaborate with attorneys in our patent litigation, products litigation, employment and tax practices to protect client interests and to advocate on their behalf.
With a full service team of highly experienced lawyers resident in key life sciences hubs, our team helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle. Motivated by the knowledge that the work that we do with you is improving people’s lives, we serve as an extension of your team so you can focus on your core business.
In the face of a competitive marketplace, elite private equity firms expect counsel with extensive experience and a stable of blue chip relationships. That’s why private equity firms have been entrusting their deals to Goodwin for decades. We believe our position to be unique within BigLaw given the collaboration of our private equity team with our robust life sciences, technology and healthcare practices. With our largest and strongest practices working together, Goodwin is exceptionally suited to address whatever the future brings.
Our Private Equity team ranks as one of the top in the United States, and we are on a trajectory of rapid ascent, both in the U.S. and abroad. The group is a market leader in the expansive middle market sector, having earned a reputation for notable buyouts, growth equity deals and growth company representations in key sectors such as technology, healthcare, financial and business services, consumer and manufacturing. And with the breakneck pace of technology disrupting industries around the world, we are uniquely positioned to partner with our clients and embrace the promise and potential of innovation.
